Molecular imaging of rheumatoid arthritis: Emerging markers, tools, and techniques

Arthritis Research and Therapy

Volumn 16, Issue 2, 2014, Pages

  Put, Stéphanie ^a   Westhovens, René ^b   Lahoutte, Tony ^c,d   Matthys, Patrick ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CHEMOKINE RECEPTOR; DENDRITIC CELL SPECIFIC TRANSMEMBRANE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FLUORODEOXYGLUCOSE F 18; FOLATE RECEPTOR; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; MACROPHAGE MANNOSE RECEPTOR; MANNOSE RECEPTOR; MATRIX METALLOPROTEINASE; MEDRONATE TECHNETIUM TC 99M; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NANOBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOCLAST STIMULATORY TRANSMEMBRANE PROTEIN; PHOSPHATIDYLSERINE; PROTEIN; PURINERGIC P2X7 RECEPTOR; RADIOPHARMACEUTICAL AGENT; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SUPPRESSION OF TUMORIGENICITY 2 PROTEIN; TRACER; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VITRONECTIN RECEPTOR; BIOLOGICAL MARKER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

BIOLUMINESCENCE; CARCINOGENICITY; CELL ADHESION; CELL SURFACE; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; DOPPLER ECHOGRAPHY; DRUG TARGETING; FLUORESCENCE IMAGING; GRAY SCALE ECHOGRAPHY; HUMAN; IN VIVO STUDY; INTRACELLULAR SIGNALING; ISOTOPE LABELING; JOINT RADIOGRAPHY; MACROPHAGE; MOLECULAR IMAGING; MOLECULAR PROBE; NEAR INFRARED IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOCLAST; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; RHEUMATOID ARTHRITIS; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASCULAR ENDOTHELIUM; PROCEDURES; B LYMPHOCYTE; CELL DIFFERENTIATION; DISEASE SEVERITY; ECHOGRAPHY; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE;

ARTHRITIS, RHEUMATOID; BIOMARKERS; HUMANS; MOLECULAR IMAGING;

EID: 84899117952     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4542     Document Type: Review

References (108)

1. Mountz JM, Alavi A, Mountz JD. Emerging optical and nuclear medicine imaging methods in rheumatoid arthritis. Nat Rev Rheumatol 2012, 8:719-728. 10.1038/nrrheum.2012.148, 23007740.
2. Conti F, Malviya G, Ceccarelli F, Priori R, Iagnocco A, Valesini G, Signore A. Role of scintigraphy with mTc-infliximab in predicting the response of intraarticular infliximab treatment in patients with refractory monoarthritis. Eur J Nucl Med Mol Imaging 2012, 39:1339-1347. 10.1007/s00259-012-2133-9, 22588625.
3. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361. 10.1038/nature01661, 12748655.
4. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2219. 10.1056/NEJMra1004965, 22150039.
5. Cascao R, Rosario HS, Souto-Carneiro MM, Fonseca JE. Neutrophils in rheumatoid arthritis: more than simple final effectors. Autoimmun Rev 2010, 9:531-535. 10.1016/j.autrev.2009.12.013, 20060506.
6. Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, Meinders AE, Breedveld FC. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997, 40:217-225. 10.1002/art.1780400206, 9041933.
7. Toh ML, Miossec P. The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol 2007, 19:284-288. 10.1097/BOR.0b013e32805e87e0, 17414957.
8. Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 2003, 5:S1-S6. 10.1186/ar1010, 15182377.
9. Svensson L, Jirholt J, Holmdahl R, Jansson L. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin Exp Immunol 1998, 111:521-526. 10.1046/j.1365-2249.1998.00529.x, 1904879, 9528892.
10. Scher JU. B-cell therapies for rheumatoid arthritis. Bull NYU Hosp Jt Dis 2012, 70:200-203.
11. Niedermeier M, Pap T, Korb A. Therapeutic opportunities in fibroblasts in inflammatory arthritis. Best Pract Res Clin Rheumatol 2010, 24:527-540.
12. Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 2012, 11:234-250. 10.1038/nrd3669, 22378270.
13. Avouac J, Uzan G, Kahan A, Boileau C, Allanore Y. Endothelial progenitor cells and rheumatic disorders. Joint Bone Spine 2008, 75:131-137. 10.1016/j.jbspin.2007.09.006, 18314371.
14. Zeman MN, Scott PJ. Current imaging strategies in rheumatoid arthritis. Am J Nucl Med Mol Imaging 2012, 2:174-220. 3477730, 23133812.
15. Szkudlarek M, Narvestad E, Klarlund M, Court-Payen M, Thomsen HS, Ostergaard M. Ultrasonography of the metatarsophalangeal joints in rheumatoid arthritis: comparison with magnetic resonance imaging, conventional radiography, and clinical examination. Arthritis Rheum 2004, 50:2103-2112. 10.1002/art.20333, 15248207.
16. Wakefield RJ, Balint PV, Szkudlarek M, Filippucci E, Backhaus M, D'Agostino MA, Sanchez EN, Iagnocco A, Schmidt WA, Bruyn GA, Kane D, O'Connor PJ, Manger B, Joshua F, Koski J, Grassi W, Lassere MN, Swen N, Kainberger F, Klauser A, Ostergaard M, Brown AK, Machold KP, Conaghan PG, OMERACT 7 Special Interest Group Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 2005, 32:2485-2487. OMERACT 7 Special Interest Group.
17. Klarlund M, Ostergaard M, Jensen KE, Madsen JL, Skjodt H, Lorenzen I. Magnetic resonance imaging, radiography, and scintigraphy of the finger joints: one year follow up of patients with early arthritis, The TIRA Group. Ann Rheum Dis 2000, 59:521-528. 1753194, 10873961.
18. McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, McLean L. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998, 57:350-356. 1752612, 9771209.
19. Savnik A, Malmskov H, Thomsen HS, Graff LB, Nielsen H, Danneskiold-Samsoe B, Boesen J, Bliddal H. MRI of the wrist and finger joints in inflammatory joint diseases at 1-year interval: MRI features to predict bone erosions. Eur Radiol 2002, 12:1203-1210. 10.1007/s003300101114, 11976868.
20. McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, McLean L. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann Rheum Dis 1999, 58:156-163. 1752839, 10364913.
21. McQueen FM, Benton N, Crabbe J, Robinson E, Yeoman S, McLean L, Stewart N. What is the fate of erosions in early rheumatoid arthritis? Tracking individual lesions using x rays and magnetic resonance imaging over the first two years of disease. Ann Rheum Dis 2001, 60:859-868. 1753833, 11502613.
22. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363:446-448. 10.1038/363446a0, 8502296.
23. Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, Cauerhff A, Danquah W, Rissiek B, Scheuplein F, Schwarz N, Adriouch S, Boyer O, Seman M, Licea A, Serreze DV, Goldbaum FA, Haag F, Koch-Nolte F. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol 2009, 198:157-174. 10.1007/s00430-009-0116-7, 2714450, 19529959.
24. De Groeve K, Deschacht N, De Koninck C, Caveliers V, Lahoutte T, Devoogdt N, Muyldermans S, De Baetselier P, Raes G. Nanobodies as tools for in vivo imaging of specific immune cell types. J Nucl Med 2010, 51:782-789. 10.2967/jnumed.109.070078, 20395332.
25. Schoonooghe S, Laoui D, Van Ginderachter JA, Devoogdt N, Lahoutte T, De Baetselier P, Raes G. Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer. Immunobiology 2012, 217:1266-1272. 10.1016/j.imbio.2012.07.009, 22884356.
26. Oliveira S, van Dongen GA, Stigter-van Walsum M, Roovers RC, Stam JC, Mali W, Van Diest PJ, Henegouwen PM V. Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol Imaging 2012, 11:33-46.
27. Hernot S, Unnikrishnan S, Du Z, Shevchenko T, Cosyns B, Broisat A, Toczek J, Caveliers V, Muyldermans S, Lahoutte T, Klibanov AL, Devoogdt N. Nanobody-coupled microbubbles as novel molecular tracer. J Control Release 2012, 158:346-353. 10.1016/j.jconrel.2011.12.007, 3294017, 22197777.
28. Broisat A, Hernot S, Toczek J, De Vos J, Riou LM, Martin S, Ahmadi M, Thielens N, Wernery U, Caveliers V, Muyldermans S, Lahoutte T, Fagret D, Ghezzi C, Devoogdt N. Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. Circ Res 2012, 110:927-937. 10.1161/CIRCRESAHA.112.265140, 3918224, 22461363.
29. Movahedi K, Schoonooghe S, Laoui D, Houbracken I, Waelput W, Breckpot K, Bouwens L, Lahoutte T, De Baetselier P, Raes G, Devoogdt N, Van Ginderachter JA. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res 2012, 72:4165-4177. 10.1158/0008-5472.CAN-11-2994, 22719068.
30. Irmler IM, Opfermann T, Gebhardt P, Gajda M, Brauer R, Saluz HP, Kamradt T. In vivo molecular imaging of experimental joint inflammation by combined (18)F-FDG positron emission tomography and computed tomography. Arthritis Res Ther 2010, 12:R203. 10.1186/ar3176, 3046507, 21047399.
31. Elzinga EH, van der Laken CJ, Comans EF, Boellaard R, Hoekstra OS, Dijkmans BA, Lammertsma AA, Voskuyl AE. 18 F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med 2011, 52:77-80. 10.2967/jnumed.110.076711, 21149486.
32. Elzinga EH, van der Laken CJ, Comans EF, Lammertsma AA, Dijkmans BA, Voskuyl AE. 2-Deoxy-2-[F-18]fluoro-D-glucose joint uptake on positron emission tomography images: rheumatoid arthritis versus osteoarthritis. Mol Imaging Biol 2007, 9:357-360. 10.1007/s11307-007-0113-4, 2040173, 17902022.
33. Sahin M, Bernay I, Basoglu T, Canturk F. Comparison of Tc-99 m MDP, Tc-99 m HSA and Tc-99 m HIG uptake in rheumatoid arthritis and its variants. Ann Nucl Med 1999, 13:389-395. 10.1007/BF03164932, 10656272.
34. Wong KK, Piert M. Dynamic bone imaging with 99mTc-labeled diphosphonates and 18 F-NaF: mechanisms and applications. J Nucl Med 2013, 54:590-599. 10.2967/jnumed.112.114298, 23482667.
35. Goerres GW, Forster A, Uebelhart D, Seifert B, Treyer V, Michel B, von Schulthess GK, Kaim AH. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med 2006, 31:386-390. 10.1097/01.rlu.0000222678.95218.42, 16785804.
36. Roivainen A, Parkkola R, Yli-Kerttula T, Lehikoinen P, Viljanen T, Mottonen T, Nuutila P, Minn H. Use of positron emission tomography with methyl-11C-choline and 2-18 F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum 2003, 48:3077-3084. 10.1002/art.11282, 14613269.
37. Roivainen A, Yli-Kerttula T. Whole-body distribution of C-choline and uptake in knee synovitis. Eur J Nucl Med Mol Imaging 2006, 33:1372-1373. 10.1007/s00259-006-0184-5, 16865392.
38. de Bois MH, Westedt ML, Arndt JW, Wiarda KS, van der Velde EA, Pauwels EK, Breedveld FC. Value of 99mTc-IgG scintigraphy in the prediction of joint destruction in patients with rheumatoid arthritis of recent onset. Rheumatol Int 1995, 15:155-158. 10.1007/BF00301773, 8835297.
39. Pons F, Sanmarti R, Herranz R, Collado A, Piera C, Vidal-Sicart S, Munoz-Gomez J, Setoain J. Scintigraphic evaluation of the severity of inflammation of the joints with 99TCm-HIG in rheumatoid arthritis. Nucl Med Commun 1996, 17:523-528. 10.1097/00006231-199606000-00012, 8822752.
40. Bennink RJ, Thurlings RM, van Hemert FJ, Voermans C, Dohmen SE, van Eck-Smit BL, Tak PP, Busemann-Sokole E. Biodistribution and radiation dosimetry of 99mTc-HMPAO-labeled monocytes in patients with rheumatoid arthritis. J Nucl Med 2008, 49:1380-1385. 10.2967/jnumed.108.051755, 18632808.
41. Caveliers V, Goodbody AE, Tran LL, Peers SH, Thornback JR, Bossuyt A. Evaluation of 99mTc-RP128 as a potential inflammation imaging agent: human dosimetry and first clinical results. J Nucl Med 2001, 42:154-161.
42. Kinne RW, Becker W, Schwab J, Schwarz A, Kalden JR, Emmrich F, Burmester GR, Wolf F. Imaging rheumatoid arthritis joints with technetium-99 m labelled specific anti-CD4- and non-specific monoclonal antibodies. Eur J Nucl Med 1994, 21:176-180.
43. Kinne RW, Emmrich F, Freesmeyer M. Clinical impact of radiolabeled anti-CD4 antibodies in the diagnosis of rheumatoid arthritis. Q J Nucl Med Mol Imaging 2010, 54:629-638.
44. Becker W, Emmrich F, Horneff G, Burmester G, Seiler F, Schwarz A, Kalden J, Wolf F. Imaging rheumatoid arthritis specifically with technetium 99 m CD4-specific (T-helper lymphocytes) antibodies. Eur J Nucl Med 1990, 17:156-159. 10.1007/BF00811445, 2149102.
45. Kinne RW, Becker W, Schwab J, Horneff G, Schwarz A, Kalden JR, Emmrich F, Burmester GR, Wolf F. Comparison of 99Tcm-labelled specific murine anti-CD4 monoclonal antibodies and nonspecific human immunoglobulin for imaging inflamed joints in rheumatoid arthritis. Nucl Med Commun 1993, 14:667-675. 10.1097/00006231-199308000-00007, 8371892.
46. Marcus C, Thakur ML, Huynh TV, Louie JS, Leibling M, Minami C, Diggles L. Imaging rheumatic joint diseases with anti-T lymphocyte antibody OKT-3. Nucl Med Commun 1994, 15:824-830. 10.1097/00006231-199410000-00008, 7838446.
47. Martins FP, Gutfilen B, de Souza SA, de Azevedo MN, Cardoso LR, Fraga R, da Fonseca LM. Monitoring rheumatoid arthritis synovitis with 99mTc-anti-CD3. Br J Radiol 2008, 81:25-29.
48. Lopes FP, de Azevedo MN, Marchiori E, da Fonseca LM, de Souza SA, Gutfilen B. Use of 99mTc-anti-CD3 scintigraphy in the differential diagnosis of rheumatic diseases. Rheumatology (Oxford) 2010, 49:933-939.
49. Barrera P, van der Laken CJ, Boerman OC, Oyen WJ, van de Ven MT, van Lent PL, van de Putte LB, Corstens FH. Radiolabelled interleukin-1 receptor antagonist for detection of synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:870-874.
50. Conti F, Priori R, Chimenti MS, Coari G, Annovazzi A, Valesini G, Signore A. Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: a role for scintigraphy with 99mTc-infliximab. Arthritis Rheum 2005, 52:1224-1226. 10.1002/art.20979, 15818709.
51. Barrera P, Oyen WJ, Boerman OC, van Riel PL. Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62:825-828. 1754647, 12922953.
52. Roimicher L, Lopes FP, de Souza SA, Mendes LF, Domingues RC, da Fonseca LM, Gutfilen B. (99 m)Tc-anti-TNF-alpha scintigraphy in RA: a comparison pilot study with MRI and clinical examination. Rheumatology (Oxford) 2011, 50:2044-2050.
53. Tran L, Huitema AD, van Rijswijk MH, Dinant HJ, Baars JW, Beijnen JH, Vogel WV. CD20 antigen imaging with I-rituximab PET/CT in patients with rheumatoid arthritis. Hum Antibodies 2011, 20:29-35.
54. Malviya G, Anzola KL, Podesta E, Lagana B, Del Mastro C, Dierckx RA, Scopinaro F, Signore A. (99 m)Tc-labeled rituximab for imaging B lymphocyte infiltration in inflammatory autoimmune disease patients. Mol Imaging Biol 2012, 14:637-646. 10.1007/s11307-011-0527-x, 3443359, 22127469.
55. Miot-Noirault E, Perin F, Routledge L, Normier G, Le Pape A. Macrophage targeting with technetium-99 m labelled J001 acylated poly-galactoside for scintigraphy of inflammation: optimization and assessment of imaging specificity in experimental arthritis. Eur J Nucl Med 1996, 23:61-68. 10.1007/BF01736991, 8586104.
56. Vanhagen PM, Markusse HM, Lamberts SW, Kwekkeboom DJ, Reubi JC, Krenning EP. Somatostatin receptor imaging. The presence of somatostatin receptors in rheumatoid arthritis. Arthritis Rheum 1994, 37:1521-1527. 10.1002/art.1780371017, 7945479.
57. van der Laken CJ, Elzinga EH, Kropholler MA, Molthoff CF, van der Heijden JW, Maruyama K, Boellaard R, Dijkmans BA, Lammertsma AA, Voskuyl AE. Noninvasive imaging of macrophages in rheumatoid synovitis using 11C-(R)-PK11195 and positron emission tomography. Arthritis Rheum 2008, 58:3350-3355. 10.1002/art.23955, 18975347.
58. Gent YY, Voskuyl AE, Kloet RW, van Schaardenburg D, Hoekstra OS, Dijkmans BA, Lammertsma AA, van der Laken CJ. Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: findings of a prospective pilot study. Arthritis Rheum 2012, 64:62-66. 10.1002/art.30655, 21898356.
59. Zinn KR, Chaudhuri TR, Smyth CA, Wu Q, Liu HG, Fleck M, Mountz JD, Mountz JM. Specific targeting of activated endothelium in rat adjuvant arthritis with a 99mTc-radiolabeled E-selectin-binding peptide. Arthritis Rheum 1999, 42:641-649. 10.1002/1529-0131(199904)42:4<641::AID-ANR6>3.0.CO;2-T, 10211877.
60. Jamar F, Houssiau FA, Devogelaer JP, Chapman PT, Haskard DO, Beaujean V, Beckers C, Manicourt DH, Peters AM. Scintigraphy using a technetium 99 m-labelled anti-E-selectin Fab fragment in rheumatoid arthritis. Rheumatology (Oxford) 2002, 41:53-61.
61. Gompels LL, Madden L, Lim NH, Inglis JJ, McConnell E, Vincent TL, Haskard DO, Paleolog EM. In vivo fluorescence imaging of E-selectin: quantitative detection of endothelial activation in a mouse model of arthritis. Arthritis Rheum 2011, 63:107-117. 10.1002/art.30082, 20954188.
62. Post AM, Katsikis PD, Tait JF, Geaghan SM, Strauss HW, Blankenberg FG. Imaging cell death with radiolabeled annexin V in an experimental model of rheumatoid arthritis. J Nucl Med 2002, 43:1359-1365.
63. Hansch A, Frey O, Sauner D, Hilger I, Haas M, Malich A, Brauer R, Kaiser WA. In vivo imaging of experimental arthritis with near-infrared fluorescence. Arthritis Rheum 2004, 50:961-967. 10.1002/art.20112, 15022340.
64. Sugimoto K, Nishimoto N, Kishimoto T, Yoshizaki K, Nishimura T. Imaging of lesions in a murine rheumatoid arthritis model with a humanized anti-interleukin-6 receptor antibody. Ann Nucl Med 2005, 19:261-266. 10.1007/BF02984617, 16097634.
65. Paulos CM, Turk MJ, Breur GJ, Low PS. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 2004, 56:1205-1217. 10.1016/j.addr.2004.01.012, 15094216.
66. Turk MJ, Breur GJ, Widmer WR, Paulos CM, Xu LC, Grote LA, Low PS. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum 2002, 46:1947-1955. 10.1002/art.10405, 12124880.
67. Matteson EL, Lowe VJ, Prendergast FG, Crowson CS, Moder KG, Morgenstern DE, Messmann RA, Low PS. Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan. Clin Exp Rheumatol 2009, 27:253-259.
68. Chen WT, Mahmood U, Weissleder R, Tung CH. Arthritis imaging using a near-infrared fluorescence folate-targeted probe. Arthritis Res Ther 2005, 7:R310-R317. 10.1186/ar1483, 1065321, 15743478.
69. Gent YY, Weijers K, Molthoff CF, Windhorst AD, Huisman MC, Smith DE, Kularatne SA, Jansen G, Low PS, Lammertsma AA, van der Laken CJ. Evaluation of the novel folate receptor ligand [18 F]fluoro-PEG-folate for macrophage targeting in a rat model of arthritis. Arthritis Res Ther 2013, 15:R37. 10.1186/ar4191, 3672671, 23452511.
70. Zheleznyak A, Wadas TJ, Sherman CD, Wilson JM, Kostenuik PJ, Weilbaecher KN, Anderson CJ. Integrin alpha(v)beta as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation. Mol Imaging Biol 2012, 14:500-508. 10.1007/s11307-011-0512-4, 21853370.
71. Ryu JH, Lee A, Chu JU, Koo H, Ko CY, Kim HS, Yoon SY, Kim BS, Choi K, Kwon IC, Kim K, Youn I. Early diagnosis of arthritis in mice with collagen-induced arthritis, using a fluorogenic matrix metalloproteinase 3-specific polymeric probe. Arthritis Rheum 2011, 63:3824-3832. 10.1002/art.30628, 22127700.
72. Put S, Schoonooghe S, Devoogdt N, Schurgers E, Avau A, Mitera T, D'Huyvetter M, De Baetselier P, Raes G, Lahoutte T, Matthys P. SPECT imaging of joint inflammation with nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis. J Nucl Med 2013, 54:807-814. 10.2967/jnumed.112.111781, 23447654.
73. Kinne RW, Becker W, Simon G, Paganelli G, Palombo-Kinne E, Wolski A, Bloch S, Schwarz A, Wolf F, Emmrich F. Joint uptake and body distribution of a technetium-99 m-labeled anti-rat-CD4 monoclonal antibody in rat adjuvant arthritis. J Nucl Med 1993, 34:92-98.
74. Kinne RW, Becker W, Koscheck T, Kuhlmann J, Sharkey RM, Behr T, Palombo-Kinne E, Goldenberg DM, Wolf F, Emmrich F. Rat adjuvant arthritis: imaging with technetium-99 m-anti-CD4 Fab' fragments. J Nucl Med 1995, 36:2268-2275.
75. Kneitz C, Wilhelm M, Tony HP. Improvement of refractory rheumatoid arthritis after depletion of B cells. Scand J Rheumatol 2004, 33:82-86. 10.1080/03009740310004379, 15163108.
76. Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Greenberg JD. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis 2014, Jan 29. doi: 10.1136/annrheumdis-2013-203936. [Epub ahead of print].
77. Finckh A, Ciurea A, Brulhart L, Moller B, Walker UA, Courvoisier D, Kyburz D, Dudler J, Gabay C. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?. Ann Rheum Dis 2010, 69:387-393. 2800201, 19416802.
78. Antony AC. Folate receptors. Annu Rev Nutr 1996, 16:501-521. 10.1146/annurev.nu.16.070196.002441, 8839936.
79. Nakashima-Matsushita N, Homma T, Yu S, Matsuda T, Sunahara N, Nakamura T, Tsukano M, Ratnam M, Matsuyama T. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1999, 42:1609-1616. 10.1002/1529-0131(199908)42:8<1609::AID-ANR7>3.0.CO;2-L, 10446858.
80. Henne WA, Rothenbuhler R, Ayala-Lopez W, Xia W, Varghese B, Low PS. Imaging sites of infection using a 99mTc-labeled folate conjugate targeted to folate receptor positive macrophages. Mol Pharm 2012, 9:1435-1440.
81. Bilthariya U, Jain N, Rajoriya V, Jain AK. Folate-conjugated albumin nanoparticles for rheumatoid arthritis-targeted delivery of etoricoxib. Drug Dev Ind Pharm 2013, Oct 28. [Epub ahead of print].
82. Xia W, Hilgenbrink AR, Matteson EL, Lockwood MB, Cheng JX, Low PS. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 2009, 113:438-446.
83. Gazi U, Martinez-Pomares L. Influence of the mannose receptor in host immune responses. Immunobiology 2009, 214:554-561. 10.1016/j.imbio.2008.11.004, 19162368.
84. Bullard DC, Hurley LA, Lorenzo I, Sly LM, Beaudet AL, Staite ND. Reduced susceptibility to collagen-induced arthritis in mice deficient in intercellular adhesion molecule-1. J Immunol 1996, 157:3153-3158.
85. Lee SI, Lee SY, Yoon KH, Choi KS, Jang KY, Yoo WH, Kim SH, Choi TH, Park JG. Molecular MR imaging for visualizing ICAM-1 expression in the inflamed synovium of collagen-induced arthritic mice. Korean J Radiol 2009, 10:472-480. 10.3348/kjr.2009.10.5.472, 2731865, 19721832.
86. Firestein GS, Yeo M, Zvaifler NJ. Apoptosis in rheumatoid arthritis synovium. J Clin Invest 1995, 96:1631-1638. 10.1172/JCI118202, 185789, 7657832.
87. Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci 2008, 1143:123-150. 10.1196/annals.1443.016, 19076348.
88. Choi Y, Arron JR, Townsend MJ. Promising bone-related therapeutic targets for rheumatoid arthritis. Nat Rev Rheumatol 2009, 5:543-548. 10.1038/nrrheum.2009.175, 2797318, 19798028.
89. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008, 58:1299-1309. 10.1002/art.23417, 18438830.
90. Iranikhah M, Wilborn TW, Wensel TM, Ferrell JB. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor. Pharmacotherapy 2012, 32:274-284. 10.1002/j.1875-9114.2011.01092.x, 22392458.
91. Atkins GJ, Kostakis P, Vincent C, Farrugia AN, Houchins JP, Findlay DM, Evdokiou A, Zannettino AC. RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 2006, 21:1339-1349. 10.1359/jbmr.060604, 16939392.
92. Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D, Russo A, Vincenzi B, Fratto ME, Sabbatini R, Della Pepa C, Porta C, Del Conte A, Schiavon G, Berruti A, Tomasino RM, Papotti M, Papapietro N, Onetti Muda A, Denaro V, Tonini G. Expression pattern of receptor activator of NFkappaB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol 2011, 226:780-784. 10.1002/jcp.22402, 20857484.
93. Ibrahim T, Sacanna E, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Ricci R, Serra L, Kang Y, Amadori D. Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. Clin Breast Cancer 2011, 11:369-375. 10.1016/j.clbc.2011.05.001, 21764390.
94. Zhang L, Teng Y, Zhang Y, Liu J, Xu L, Qu J, Hou K, Yang X, Liu Y, Qu X. Receptor activator for nuclear factor kappa B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis. J Clin Pathol 2012, 65:36-40. 10.1136/jclinpath-2011-200312, 22049226.
95. Tak PP, Balanescu A, Tseluyko V, Bojin S, Drescher E, Dairaghi D, Miao S, Marchesin V, Jaen J, Schall TJ, Bekker P. Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann Rheum Dis 2013, 72:337-344.
96. Suzuki N, Nakajima A, Yoshino S, Matsushima K, Yagita H, Okumura K. Selective accumulation of CCR5+ T lymphocytes into inflamed joints of rheumatoid arthritis. Int Immunol 1999, 11:553-559. 10.1093/intimm/11.4.553, 10323208.
97. Yang YF, Mukai T, Gao P, Yamaguchi N, Ono S, Iwaki H, Obika S, Imanishi T, Tsujimura T, Hamaoka T, Fujiwara H. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur J Immunol 2002, 32:2124-2132. 10.1002/1521-4141(200208)32:8<2124::AID-IMMU2124>3.0.CO;2-S, 12209624.
98. Okamoto H, Kamatani N. A CCR-5 antagonist inhibits the development of adjuvant arthritis in rats. Rheumatology (Oxford) 2006, 45:230-232.
99. Matsuyama T, Kitani A. The role of VCAM-1 molecule in the pathogenesis of rheumatoid synovitis. Hum Cell 1996, 9:187-192.
100. Lowin T, Straub RH. Integrins and their ligands in rheumatoid arthritis. Arthritis Res Ther 2011, 13:244. 10.1186/ar3464, 3308078, 22077951.
101. Wilder RL. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis 2002, 61:ii96-ii99. 1766704, 12379637.
102. Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL. c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest 2003, 111:749-758. 10.1172/JCI200316924, 151897, 12618529.
103. Caporali F, Capecchi PL, Gamberucci A, Lazzerini PE, Pompella G, Natale M, Lorenzini S, Selvi E, Galeazzi M, Laghi Pasini F. Human rheumatoid synoviocytes express functional P2X7 receptors. J Mol Med (Berl) 2008, 86:937-949.
104. Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P, Payette MM, Brissette W, Wicks JR, Audoly L, Gabel CA. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol 2002, 168:6436-6445.
105. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004, 173:145-150.
106. Miyamoto H, Suzuki T, Miyauchi Y, Iwasaki R, Kobayashi T, Sato Y, Miyamoto K, Hoshi H, Hashimoto K, Yoshida S, Hao W, Mori T, Kanagawa H, Katsuyama E, Fujie A, Morioka H, Matsumoto M, Chiba K, Takeya M, Toyama Y, Miyamoto T. Osteoclast stimulatory transmembrane protein and dendritic cell-specific transmembrane protein cooperatively modulate cell-cell fusion to form osteoclasts and foreign body giant cells. J Bone Miner Res 2012, 27:1289-1297. 10.1002/jbmr.1575, 22337159.
107. Chiu YH, Mensah KA, Schwarz EM, Ju Y, Takahata M, Feng C, McMahon LA, Hicks DG, Panepento B, Keng PC, Ritchlin CT. Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res 2012, 27:79-92. 10.1002/jbmr.531, 3304467, 21987375.
108. Smolen JS, Aletaha D. Forget personalised medicine and focus on abating disease activity. Ann Rheum Dis 2013, 72:3-6.